PURPOSE: Since apoptosis may play a role in the prognosis of breast cancer, the present study analyzed the polymorphisms of apoptosis-related genes and their impact on the survival of 240 patients with early invasive ductal breast cancer. METHODS: The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and 12 single nucleotide polymorphisms (SNPs) of 11 apoptosis-related genes in the apoptosis pathway determined using a Sequenom MassARRAY system. RESULTS: During the median follow-up of 53.4 (range 2.9-205.9) months, 37 relapses and 22 deaths occurred. Among the target polymorphisms, the tumor necrosis factor superfamily member 10 gene polymorphism (TNFSF10 rs1131532) in a recessive model of the T allele and prostaglandin-endoperoxide synthase 2 gene polymorphism (PTGS2 rs5275) in a dominant model of the C allele were associated with survival in a log-rank test. The TT genotype of TNFSF10 (rs1131532) was also significantly correlated with a lower disease-free, distant disease-free, and overall survival in a multivariate analysis (HR = 3.304, 4.757, and 6.459; P = 0.002, 0.001, and 0.009, respectively), while PTGS2 rs5275 was only associated with a higher distant disease-free survival (HR = 0.302; P = 0.041). No clinicopathologic difference was observed according to the genotypes of these two polymorphisms. CONCLUSION: The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.
PURPOSE: Since apoptosis may play a role in the prognosis of breast cancer, the present study analyzed the polymorphisms of apoptosis-related genes and their impact on the survival of 240 patients with early invasive ductal breast cancer. METHODS: The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and 12 single nucleotide polymorphisms (SNPs) of 11 apoptosis-related genes in the apoptosis pathway determined using a Sequenom MassARRAY system. RESULTS: During the median follow-up of 53.4 (range 2.9-205.9) months, 37 relapses and 22 deaths occurred. Among the target polymorphisms, the tumor necrosis factor superfamily member 10 gene polymorphism (TNFSF10rs1131532) in a recessive model of the T allele and prostaglandin-endoperoxide synthase 2 gene polymorphism (PTGS2rs5275) in a dominant model of the C allele were associated with survival in a log-rank test. The TT genotype of TNFSF10 (rs1131532) was also significantly correlated with a lower disease-free, distant disease-free, and overall survival in a multivariate analysis (HR = 3.304, 4.757, and 6.459; P = 0.002, 0.001, and 0.009, respectively), while PTGS2rs5275 was only associated with a higher distant disease-free survival (HR = 0.302; P = 0.041). No clinicopathologic difference was observed according to the genotypes of these two polymorphisms. CONCLUSION: The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.
Authors: M S Shin; H S Kim; S H Lee; W S Park; S Y Kim; J Y Park; J H Lee; S K Lee; S N Lee; S S Jung; J Y Han; H Kim; J Y Lee; N J Yoo Journal: Cancer Res Date: 2001-07-01 Impact factor: 12.701
Authors: Jianming Wu; Christine Metz; Xiulong Xu; Riichiro Abe; Andrew W Gibson; Jeffrey C Edberg; Jennifer Cooke; Fenglong Xie; Glinda S Cooper; Robert P Kimberly Journal: J Immunol Date: 2003-01-01 Impact factor: 5.422
Authors: Jung Min Park; Jin Eun Choi; Myung Hwa Chae; Won Kee Lee; Sung Ick Cha; Ji-Woong Son; Chang Ho Kim; Sin Kam; Young Mo Kang; Tae Hoon Jung; Jae Yong Park Journal: BMC Cancer Date: 2006-03-17 Impact factor: 4.430
Authors: James L Murray; Patricia Thompson; Suk Young Yoo; Kim-Anh Do; Mala Pande; Renke Zhou; Yanhong Liu; Aysegul A Sahin; Melissa L Bondy; Abenaa M Brewster Journal: Breast Cancer Res Treat Date: 2013-03-26 Impact factor: 4.872
Authors: Nicole A Lavender; Erica N Rogers; Susan Yeyeodu; James Rudd; Ting Hu; Jie Zhang; Guy N Brock; Kevin S Kimbro; Jason H Moore; David W Hein; La Creis R Kidd Journal: BMC Med Genomics Date: 2012-04-30 Impact factor: 3.063
Authors: Silvia von der Heyde; Steve Wagner; Alexander Czerny; Manuel Nietert; Fabian Ludewig; Gabriela Salinas-Riester; Dorit Arlt; Tim Beißbarth Journal: PLoS One Date: 2015-02-24 Impact factor: 3.240
Authors: Jan Baijer; Nathalie Déchamps; Hervé Perdry; Pablo Morales; Sarah Kerns; Alexandre Vasilescu; Sylvain Baulande; David Azria; Paul Henri Roméo; Annette Schmitz Journal: Oncotarget Date: 2016-04-19
Authors: Arancha Cebrián; Teresa Gómez Del Pulgar; María José Méndez-Vidal; María Luisa Gonzálvez; Nuria Lainez; Daniel Castellano; Iciar García-Carbonero; Emilio Esteban; Maria Isabel Sáez; Rosa Villatoro; Cristina Suárez; Alfredo Carrato; Javier Munárriz-Ferrándiz; Laura Basterrechea; Mirta García-Alonso; José Luis González-Larriba; Begoña Perez-Valderrama; Josefina Cruz-Jurado; Aránzazu González Del Alba; Fernando Moreno; Gaspar Reynés; María Rodríguez-Remírez; Valentina Boni; Ignacio Mahillo-Fernández; Yolanda Martin; Andrea Viqueira; Jesús García-Foncillas Journal: Sci Rep Date: 2017-01-24 Impact factor: 4.379
Authors: Samia S Messeha; Najla O Zarmouh; Patricia Mendonca; Hayfaa Alwagdani; Carolyn Cotton; Karam F A Soliman Journal: Oncol Rep Date: 2019-05-31 Impact factor: 3.906